DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



NIS-Observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Moderate/Severe Asthma

Phase: N/A

Status: Not yet recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Cristina Pentiuc, Study Chair, Affiliation: AstraZeneca

Overall contact:
AstraZeneca Romania Clinical Study Information, Phone: +4021 317 60 41, Email: diana.omer@astrazeneca.com

Summary

The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period

Clinical Details

Official title: SMART Way of Treating Asthma. Non-Interventional Study to Evaluate Clinical Efficacy of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Patients With Moderate and Severe Asthma

Study design: Cohort, Prospective

Primary outcome: Asthma Control Questionnaire ACQ

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- patients eligible for entry into study are the patients diagnosed with moderate to

severe asthma, that the doctors have already decided to treat with Symbicort SMART within the last month, before inclusion in this program

- All eligible patients will be included in the protocol provided they will receive

detailed information in advance and will sign consent to grant access to their own data collected during this programme.

Exclusion Criteria:

- All the patients who have a known hypersensitivity to Symbicort or any of its

excipients will not be included in this study.

- As per valid Romanian SmPC, concomitant medication, that could result in drug

interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.

Locations and Contacts

AstraZeneca Romania Clinical Study Information, Phone: +4021 317 60 41, Email: diana.omer@astrazeneca.com

Research Site, Alba Iulia, Romania

Research Site, Alexandria, Romania

Research Site, Arad, Romania

Research Site, Bacau, Romania

Research Site, Baia Mare, Romania

Research Site, Botosani, Romania

Research Site, Braila, Romania

Research Site, Brasov, Romania

Research Site, Breaza, Romania

Research Site, Bucuresti, Romania

Research Site, Buftea, Romania

Research Site, Calarasi, Romania

Research Site, Campina, Romania

Research Site, Campulung, Romania

Research Site, Cluj Napoca, Romania

Research Site, Constanta, Romania

Research Site, Craiova, Romania

Research Site, Deva, Romania

Research Site, Drobeta Turnu Severin, Romania

Research Site, Giurgiu, Romania

Research Site, Hunedoara, Romania

Research Site, Iasi, Romania

Research Site, Leordeni, Romania

Research Site, Miercurea Ciuc, Romania

Research Site, Mizil, Romania

Research Site, Oradea, Romania

Research Site, Palazu Mare, Romania

Research Site, Piatra Neamt, Romania

Research Site, Pitesti, Romania

Research Site, Ploiesti, Romania

Research Site, Resita, Romania

Research Site, Rm. Valcea, Romania

Research Site, Scornicesti, Romania

Research Site, Sf. Gheorghe, Romania

Research Site, Sibiu, Romania

Research Site, Slobozia, Romania

Research Site, Suceava, Romania

Research Site, Targoviste, Romania

Research Site, Targu Mures, Romania

Research Site, Tg. Jiu, Romania

Research Site, Timisoara, Romania

Research Site, Tulcea, Romania

Research Site, Vaslui, Romania

Research Site, Zalau, Romania

Additional Information

Starting date: November 2008
Last updated: March 26, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009